Recent News

• 08.04.2026 - IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.31.2026 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 07.27.2026 - IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
• 07.17.2026 - IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
• 06.26.2026 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 06.17.2026 - IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
• 06.15.2026 - IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
• 06.11.2026 - Reflections from ASCO 2026: The Future of Cancer Care Shows Progress, Possibility, and Promise
• 06.10.2026 - IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
• 06.10.2026 - IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Recent Filings

• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report
• 08.04.2026 - EX-99.1 EX-99.1
• 07.31.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.07.2026 - 144 Report of proposed sale of securities
• 06.23.2026 - 8-K Current report
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities